Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Stanford University, Stanford, CA, United States

Survival: 9.0 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: Stanford, CA
Hospital: Stanford University
Journal: Link
Date: 7/2013

This phase 2 study involved 14 recurrent diffuse large B cell lymphoma patients who had been previously treated. The median patient age was 69.5 years and 9 were male.

Patients were treated with the biologic therapy agent sorafenib, which is a protein kinase inhibitor that is involved in the growth of cancer cells.

The most severe toxicities were of grade 4 and included fatigue and low platelet count. Grade 3 rash and diarrhea were also reported.

The median overall survival was 9 months.

One of the authors of the study is employed by the Roche-Genentech pharmaceutical company.

Correspondence: Dr. Daniel R Greenwald; email:

E-mail to a Friend Email Physician More Information